Allterum Therapeutics

About Allterum Therapeutics

Allterum Therapeutics is a biopharmaceutical company based in Houston, TX, founded in 2018 by Fannin. The company focuses on targeting the IL-7 pathway to develop treatments for CD127 expressing cancers, aiming to address critical unmet medical needs in oncology.

Products & Services

Monoclonal Antibody against CD127 (IL-7Rα):A therapy targeting CD127 expressing cancers, initially focused on relapsed/refractory hematologic malignancies such as T-cell ALL and B-cell cancers, with potential applications in lymphomas and solid tumors with CD127 over-expression.

Specialties

IL-7 Pathway Targeting CD127 Expressing Cancer Treatments Monoclonal Antibody Development Relapsed/Refractory Hematologic Malignancies Lymphomas and Solid Tumors with CD127 Over-expression

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: SBIR Phase II Grant T: - FT: SBIR Phase II Grant	A: 2000000 MR: - FA: $2 million FAN: 2000000	D: 2023-05-08 FD: 2023-05-08	1 investors

SBIR Phase II Grant Latest

2023-05-08

$2.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Serena

Y

Yan Moore

CEO

LinkedIn (Pro only)

M

Mark Worscheh

Chief Financial Officer

LinkedIn (Pro only)

R

Ross Hamilton

Senior Manager, Research & Development

A

Atul Varadhachary

President/Executive Chairman

U

Uksha Saini

Senior Scientist

View 14 more team members with Pro

Unlock Full Team Directory

Recent News